Trials / Recruiting
RecruitingNCT06938880
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors, Including Cervical Cancer, Hepatocellular Carcinoma, Neuroendocrine Tumors, and Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ZGGS18 for Injection | Intravenous infusion |
| BIOLOGICAL | ZG005 for Injection | Intravenous infusion |
Timeline
- Start date
- 2025-05-20
- Primary completion
- 2027-05-01
- Completion
- 2028-04-01
- First posted
- 2025-04-22
- Last updated
- 2026-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06938880. Inclusion in this directory is not an endorsement.